Henry Schein Inc. (HSIC) stock has hit a 52-week high of $80.66, with current trading at $81.03, showing strong momentum with a 16.11% gain over the past six months, even after a slight 1-year decline. The company’s financial health is rated “GOOD” by InvestingPro, indicating investor confidence despite trading above its Fair Value. Recent developments include a new distribution agreement with CytoChip Inc. for the CitoCBC system and the appointment of Frederick M. Lowery as the new CEO starting March 2026.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Henry Schein stock hits 52-week high, reaching 80.66 USD By Investing.com
Henry Schein Inc. (HSIC) stock has hit a 52-week high of $80.66, with current trading at $81.03, showing strong momentum with a 16.11% gain over the past six months, even after a slight 1-year decline. The company’s financial health is rated “GOOD” by InvestingPro, indicating investor confidence despite trading above its Fair Value. Recent developments include a new distribution agreement with CytoChip Inc. for the CitoCBC system and the appointment of Frederick M. Lowery as the new CEO starting March 2026.